Quantitative sensory testing (QST) is a panel of diagnostic tests used to assess

somatosensory In physiology, the somatosensory system is the network of neural structures in the brain and body that produce the perception of touch (haptic perception), as well as temperature (thermoception), body position ( proprioception), and pain. It ...

function, in the context of research and as a supplemental tool in the diagnosis of somatosensory disorders, including pain insensitivity, painless and painful

neuropathy Peripheral neuropathy, often shortened to neuropathy, is a general term describing disease affecting the peripheral nerves, meaning nerves beyond the brain and spinal cord. Damage to peripheral nerves may impair sensation, movement, gland, or o ...

. The panel of tests examine a broad range of different sensations, including hot, cold, touch, vibration. It has both positive and negative tests (can test for increased or reduced sensitivity). QST reflects a formalisation of existing neurological tests into a standardised battery designed to detect subtle changes in sensory function. Large datasets representing normal responses to sensory tests have been established to quantitate deviation from the mean and allow comparison with normal patients. It is thought that a detailed evaluation of somatosensory function may be useful in identifying subtypes of pain and as a potential tool to identify

asymptomatic In medicine, any disease is classified asymptomatic if a patient tests as carrier for a disease or infection but experiences no symptoms. Whenever a medical condition fails to show noticeable symptoms after a diagnosis it might be considered a ...

neuropathy, which may represent up to 50% of total people with neuropathy (or loss of the nerve fibres). In clinical use, it is often combined with other tests such as clinical electrophysiology. In research settings it is increasingly applied in combination with advanced imaging such as

fMRI Functional magnetic resonance imaging or functional MRI (fMRI) measures brain activity by detecting changes associated with blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area ...

, epidermis "nerve" biopsies and microneurography to classify subtypes of painful disorders.

Clinical recommendations

The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) have recommended the clinical use of QST in the diagnosis and evaluation of patients with small and large fibre neuropathy as well as screening for deficits of the somatosensory system (which may include deficits in the brain for instance). The group also recommend that the technique not be used in patients in litigation, or with severe learning or cognitive deficits as it is likely to be inaccurate due to its psychophysical basis. The recommendations are based on large trials suggesting inter-test reliability of the method.

Testing battery

Standard parameters are evaluated using calibrated testing apparatus. The tests can be performed in multiple areas of the body; the areas are limited by the existing available normal sensory data. All of the tests are repeated several times. A widely used set of parameters was proposed by the German Research Network on Neuropathic Pain. Subject values are compared to normal data to determine whether the subject has a deficit in any modality.

Rationale

In addition to diagnostic confidence with neuropathy, additional reasons may encourage the use of QST.

Classification of neuropathic pain

It is thought that patients with neuropathic pain can be grouped into clusters based on their sensory profiles and that this may have a role in determining treatment. After-the fact (or Post Hoc) analysis of the responders to treatments in clinical trials have suggested different clinical responses may cluster based on phenotype and preliminary clinical trials suggest some analgesics show a greater efficacy in patient subtypes. The european medicines agency allow the classification of patients by QST in clinical trials. It is proposed that in cases where efficacy is only shown in one identified QST group, the drug will only be approved for use with those patients. Additionally, in Europe, QST is now allowed as a secondary outcome in clinical trials.

Early disease identification

Vasculitic_neuropathy_-_plastics_-_low_mag

The early identification of neuropathy particularly in diabetic neuropathy may be useful to identify people with asymptomatic neuropathy. Asymptomatic neuropathy is a clinical concern because patients with untreated neuropathy may develop ulcers and damage due to a loss of protective sensation.

Weaknesses

QST relies on psychophysical report of responses to stimuli. As a result it may be subject to patient biases. Nerve conduction studies may provide a more reliable metric in certain clinical situations. However, nerve conduction studies poorly identify hypersensitivity, QST can identify both loss and gain of function. Psychophysical tests are generally affected by other difficult to control factors, such as stress, the experience of the tester, the room the test is in, the novelty of the environment and the person's temperament. The test is time consuming and may take an hour to perform, and for monitoring require multiple visits.

References

{{Reflist, 30em Pain Neurological disorders Medical_tests